Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., … Fan, J. (2021). Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. The Lancet Oncology, 22(7), 977–990. doi:10.1016/s1470-2045(21)00252-7
